338 related articles for article (PubMed ID: 17875112)
21. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls.
Soyka M; Winter C; Kagerer S; Brunnauer M; Laux G; Möller HJ
J Psychiatr Res; 2005 Jan; 39(1):101-8. PubMed ID: 15504428
[TBL] [Abstract][Full Text] [Related]
22. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
Stanković Z; Britvić D; Vuković O; Ille T
Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
[TBL] [Abstract][Full Text] [Related]
23. [Akathisia due to risperidone withdrawal: two clinical cases].
Bertolín Guillén JM; Martínez Franco L; Juni Anahuja J
Actas Esp Psiquiatr; 2002; 30(3):195-7. PubMed ID: 12106521
[TBL] [Abstract][Full Text] [Related]
24. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.
Lee SM; Chou YH; Li MH; Wan FJ; Yen MH
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1101-7. PubMed ID: 17475386
[TBL] [Abstract][Full Text] [Related]
25. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
[TBL] [Abstract][Full Text] [Related]
26. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
[TBL] [Abstract][Full Text] [Related]
27. Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives.
Silva RR; Muñoz DM; Daniel W; Barickman J; Friedhoff AJ
J Clin Psychiatry; 1996 Mar; 57(3):129-35. PubMed ID: 8617698
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
29. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S
Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652
[TBL] [Abstract][Full Text] [Related]
30. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
Byerly MJ; Nakonezny PA; Rush AJ
Psychiatry Res; 2008 May; 159(1-2):115-20. PubMed ID: 18295343
[TBL] [Abstract][Full Text] [Related]
31. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
32. Subjective cognitive dysfunction in first-episode and chronic schizophrenic patients.
Moritz S; Lambert M; Andresen B; Böthern A; Naber D; Krausz M
Compr Psychiatry; 2001; 42(3):213-6. PubMed ID: 11349240
[TBL] [Abstract][Full Text] [Related]
33. Cerebral cortical gray expansion associated with two second-generation antipsychotics.
Garver DL; Holcomb JA; Christensen JD
Biol Psychiatry; 2005 Jul; 58(1):62-6. PubMed ID: 15992524
[TBL] [Abstract][Full Text] [Related]
34. Five-year follow-up during antipsychotic treatment: efficacy, safety, functional and social outcome.
Lindström E; Eberhard J; Levander S
Acta Psychiatr Scand Suppl; 2007; (435):5-16. PubMed ID: 17953521
[TBL] [Abstract][Full Text] [Related]
35. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
[TBL] [Abstract][Full Text] [Related]
36. Clinical decision-making during 5 years of antipsychotic treatment.
Levander S; Eberhard J; Lindström E
Acta Psychiatr Scand Suppl; 2007; (435):17-26. PubMed ID: 17953522
[TBL] [Abstract][Full Text] [Related]
37. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
[TBL] [Abstract][Full Text] [Related]
38. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB
Hum Psychopharmacol; 2008 Aug; 23(6):465-70. PubMed ID: 18536066
[TBL] [Abstract][Full Text] [Related]
39. The problem of tardive akathisia.
Gualtieri CT
Brain Cogn; 1993 Sep; 23(1):102-9. PubMed ID: 8105819
[TBL] [Abstract][Full Text] [Related]
40. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
